Skip to main content
Premium Trial:

Request an Annual Quote

NCCN Adds Mirati Therapeutics' Krazati to Guidelines for KRAS-Mutant NSCLC With Brain Metastases

NEW YORK – The National Comprehensive Cancer Network (NCCN) this week updated its guidelines to add Mirati Therapeutics' Krazati (adagrasib) as a treatment for KRAS G12C-mutant non-small cell lung cancer patients with central nervous system (CNS) metastases.

The NCCN cited previous studies showing Krazati's activity in this patient population. Mirati presented data last year showing the drug's effect on NSCLC patients with both previously treated and untreated CNS metastases. In previously treated CNS patients, one-third had an intracranial response to Krazati. Among patients with active, untreated CNS metastases, 32 percent had an intracranial response to the drug. At the time that data was presented, similar data was presented on a competing drug, Amgen's Lumakras (sotorasib), in NSCLC patients with previously treated brain metastases, with 13 percent of patients with CNS metastases responding to Lumakras.

Krazati was approved in December for patients with locally advanced or metastatic non-small cell lung cancer who have received at least one systemic therapy and who have KRAS G12C-mutated tumors. While the approval does not specifically mention patients with CNS metastases, Mirati CEO David Meek previously said on a call with investors that the firm was interested in getting the indication for KRAS-mutant NSCLC patients with untreated, active brain metastases on the Krazati label.

The NCCN Clinical Practice Guidelines in Oncology are intended to aid decision-making in cancer care for healthcare providers.